Off-label use of antibiotics in hospitalized patients: focus on tigecycline.

Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Abstract 790. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 2. Johnson M, Campbell T, Clotet B et al. DUET-2: week-48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2008. Abstract 791. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 3. Nelson M, Arastéh K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005, 40: 404–12. 4. Harris M, Larsen G, Montaner J. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008; 22: 1224–6. 5. De Castro N, Braun J, Charreau I et al. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: a randomized open-label non-inferiority trial (EASIER – ANRS 138). In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 572. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 6. Ruane P, Alas B, Fox S et al. A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimen. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P068. www.hiv9. com. 7. Matt S, Kakuda T, Hanley W et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228–32. 8. Davis J, Scholler-Gyure M, Kakuda T et al. An open, randomised, two-period, crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. In: Abstracts of the Eleventh European AIDS Conference, Madrid, Spain, 2007. Abstract P4.3/02. www.eacsconference2007. com. 9. Yazdanpanah YC, Fagard C, Descamps D et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial. In: Abstracts of the Eleventh World AIDS Conference, Mexico City, Mexico, 2007. Abstract. THAB0406. www.aids2008. org. 10. Nozza S, Visco F, Soria A et al. Excellent short-term CD4 recovery with a PIand NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P045. www.hiv9. com. 11. Imaz A, Villar del Saz S, Ribas M et al. Raltegravir, etravirine and ritonavir-boosted darunavir: a safe and successful rescue regimen for multi-drug resistant HIV-1 infection. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P040. www.hiv9. com. 12. Vingerhoets J, Peeters M, Azijn H et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. In: Abstracts of the Seventeenth International HIV Drug Resistance Workshop, Sitges, Spain, 2008. Abstract 24. www. informedhorizons.com/resistance2008/. Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkp342 Advance Access publication 16 September 2009